7-acetylamino-2-naphthalenesulfonyl chloride | 145650-54-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 7-acetylamino-2-naphthalenesulfonyl chloride
• 英文别名: 7-acetamidonaphthalene-2-sulphonyl chloride；N-[7-(chlorosulfonyl)-2-naphthyl]acetamide；7-acetamidonaphthalene-2-sulfonyl chloride
• CAS: 145650-54-0
• 化学式: C₁₂H₁₀ClNO₃S
• 分子量: 283.735
• InChiKey: UBRZEKKUMNIMNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-acetylamino-2-naphthalenesulfonyl chloride 在 三乙胺 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 氯仿 、 水 为溶剂， 反应 120.5h， 生成
  参考文献：
  名称：

  Novel symmetrical ureas as modulators of protein arginine methyl transferases

  摘要：

  Methylation of histone arginine residues is an epigenetic mark related to gene expression that is implicated in a variety of biological processes and can be reversed by small-molecule modulators of protein arginine methyltransferases (PRMTs). A series of symmetrical ureas, designed as analogues of the known PRMT1 inhibitor AMI-1 have been synthesized using Pd-catalyzed Ar-N amide bond formation processes or carbonylation reactions as key steps. Their inhibitory profile has been characterized. The enzymatic assays showed a weak effect on PRMT1 and PRMT5 activity for most of the compounds. The acyclic urea that exhibited the strongest effect on the inhibition of the PRMT1 activity also showed the greatest effect on the expression of some androgen receptor target genes (TMPRSS2 and FKBP5), which may be related with its enzymatic activity. Surprisingly, AMI-1 behaved as an activator of PRMT5 activity, a result not reported so far. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.01.017
• 作为产物：
  描述：

  7-acetamidonaphthalene-2-sulphonic acid 在 sodium methylate 、 N,N-二甲基乙酰胺 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 24.0h， 以0.115 g的产率得到7-acetylamino-2-naphthalenesulfonyl chloride
  参考文献：
  名称：

  Novel symmetrical ureas as modulators of protein arginine methyl transferases

  摘要：

  Methylation of histone arginine residues is an epigenetic mark related to gene expression that is implicated in a variety of biological processes and can be reversed by small-molecule modulators of protein arginine methyltransferases (PRMTs). A series of symmetrical ureas, designed as analogues of the known PRMT1 inhibitor AMI-1 have been synthesized using Pd-catalyzed Ar-N amide bond formation processes or carbonylation reactions as key steps. Their inhibitory profile has been characterized. The enzymatic assays showed a weak effect on PRMT1 and PRMT5 activity for most of the compounds. The acyclic urea that exhibited the strongest effect on the inhibition of the PRMT1 activity also showed the greatest effect on the expression of some androgen receptor target genes (TMPRSS2 and FKBP5), which may be related with its enzymatic activity. Surprisingly, AMI-1 behaved as an activator of PRMT5 activity, a result not reported so far. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.01.017

文献信息

• Quinoxaline compounds, their preparation and use
  申请人：NOVO NORDISK A/S

  公开号：EP0511152A3

  公开（公告）日：1993-03-03

  Quinoxaline compounds having the formula I wherein    R¹ is H, NO₂, CN, CF₃ or halogen, R² and R³ independently are H, CN, CF₃, halogen, C(NOH)C₁₋₆- alkyl, COR⁴ or SO₂R⁴, wherein R⁴ is C₁₋₆-alkyl, optionally substituted, or NR⁵R⁶, wherein R⁵, R⁶ independently are H, C₃₋₆-cycloalkyl, C₁₋₆-alkyl-, optionally substituted, compositions thereof and methods of preparing the compounds are described.The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters.

  具有公式I的喹诺克林化合物，其中R¹是H，NO₂，CN，CF₃或卤素，R²和R³独立地为H，CN，CF₃，卤素，C(NOH)C₁₋₆-烷基，COR⁴或SO₂R⁴，其中R⁴是C₁₋₆-烷基，可选地取代，或NR⁵R⁶，其中R⁵，R⁶独立地为H，C₃₋₆-环烷基，C₁₋₆-烷基，可选地取代，其组合物以及制备化合物的方法均有描述。这些化合物可用于治疗由兴奋性神经递质过度活跃引起的疾病。
• Naphthalene ureas as glucose uptake enhancers
  申请人：Telik, Inc.

  公开号：US06458998B1

  公开（公告）日：2002-10-01

  Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.

  化合物I的公式对治疗与高血糖相关的疾病，特别是2型糖尿病，具有益处。这些化合物在刺激胰岛素受体的激酶活性、激活胰岛素受体和促进葡萄糖摄取方面具有用处。还公开了包含抗糖尿病化合物的药物组合物。
• [EN] SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE MMP-12 ET MMP-13 À BASE D'ACIDE HYDROXAMIQUE
  申请人：NOVARTIS AG

  公开号：WO2010007027A1

  公开（公告）日：2010-01-21

  The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP- 13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

  本发明提供了一种具有化学式(I)的化合物，该化合物是MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-12和/或MMP-13异常活性特征的疾病或疾病。因此，化合物的化学式(I)可用于治疗由MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了包括化学式(I)的化合物的药物组合物。
• Novel naphthalene ureas as glucose uptake enhancers
  申请人：——

  公开号：US20030135063A1

  公开（公告）日：2003-07-17

  Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.

  公式I的化合物对于治疗与高血糖有关的疾病，特别是2型糖尿病非常有用。这些化合物在刺激胰岛素受体的激酶活性、激活胰岛素受体和促进葡萄糖的摄取方面非常有用。还公开了包含抗糖尿病化合物的药物组合物。
• SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS
  申请人：McQuire Leslie Wighton

  公开号：US20110112076A1

  公开（公告）日：2011-05-12

  The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

  本发明提供了一种式子为(I)的化合物，该化合物是MMP-12和/或MMP-13的抑制剂，因此可用于治疗MMP-12和/或MMP-13活性异常引起的疾病或疾病。因此，式(I)的化合物可用于治疗由MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了包括式(I)的化合物的药物组合物。